Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 5/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3777234 | 1.00 | KDM4E (0.33) | KDM4EPOLBDPP4DPP7ALDH1A1 | |
| SCHEMBL13842716 | 0.85 | POLB (0.33) | POLBDPP4DPP7ALDH1A1TP53 | |
| SCHEMBL22013224 | 0.80 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL13392941 | 0.80 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL3783917 | 0.79 | MAPT (0.39) | POLBALDH1A1TP53ALOX15TSHR | |
| SCHEMBL13015647 | 0.77 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL3776842 | 0.75 | HSD11B1 (0.42) | KDM4EPOLBALDH1A1TP53 | |
| Trifluoroacetic Acid SCHEMBL29021722 | 0.74 | DPP4 (0.41) | DPP4DPP7DPP9 | |
| SCHEMBL10171235 | 0.74 | DPP4 (0.30) | DPP4DPP9 | |
| SCHEMBL1691109 | 0.74 | GAA (0.35) | POLBALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546563-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| EP-2217565-B1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2013-05-22 | — | — | EP | disclosed |
| US-20100331304-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331304-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | KDM4E 3299/4885POLB 4500/4885DPP4 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.